Correlation Between Viridian Therapeutics and Effector Therapeutics

Can any of the company-specific risk be diversified away by investing in both Viridian Therapeutics and Effector Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Viridian Therapeutics and Effector Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Viridian Therapeutics and Effector Therapeutics, you can compare the effects of market volatilities on Viridian Therapeutics and Effector Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Viridian Therapeutics with a short position of Effector Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Viridian Therapeutics and Effector Therapeutics.

Diversification Opportunities for Viridian Therapeutics and Effector Therapeutics

-0.36

Correlation Coefficient

Viridian Therapeutics  Effector Therapeutics

Very good diversification

The 3 months correlation between Viridian and Effector is -0.36. Overlapping area represents the amount of risk that can be diversified away by holding Viridian Therapeutics and Effector Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Effector Therapeutics and Viridian Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Viridian Therapeutics are associated (or correlated) with Effector Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Effector Therapeutics has no effect on the direction of Viridian Therapeutics i.e., Viridian Therapeutics and Effector Therapeutics go up and down completely randomly.

Pair Corralation between Viridian Therapeutics and Effector Therapeutics

Given the investment horizon of 90 days Viridian Therapeutics is expected to generate 0.43 times more return on investment than Effector Therapeutics. However, Viridian Therapeutics is 2.33 times less risky than Effector Therapeutics. It trades about 0.03 of its potential returns per unit of risk. Effector Therapeutics is currently generating about -0.05 per unit of risk. If you would invest  1,990  in Viridian Therapeutics on July 20, 2024 and sell it today you would earn a total of  436.00  from holding Viridian Therapeutics or generate 21.91% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Insignificant
Accuracy	85.05%
Values	Daily Returns

Viridian Therapeutics  vs.  Effector Therapeutics

Viridian Therapeutics

Risk-Adjusted Performance

13 of 100

Good

Compared to the overall equity markets, risk-adjusted returns on investments in Viridian Therapeutics are ranked lower than 13 (%) of all global equities and portfolios over the last 90 days. In spite of very weak fundamental indicators, Viridian Therapeutics displayed solid returns over the last few months and may actually be approaching a breakup point.

Effector Therapeutics

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Effector Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Even with relatively invariable basic indicators, Effector Therapeutics is not utilizing all of its potentials. The latest stock price agitation, may contribute to short-term losses for the retail investors.

Pair Trading with Viridian Therapeutics and Effector Therapeutics

The main advantage of trading using opposite Viridian Therapeutics and Effector Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Viridian Therapeutics position performs unexpectedly, Effector Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Effector Therapeutics will offset losses from the drop in Effector Therapeutics' long position.

The idea behind Viridian Therapeutics and Effector Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.